Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.
Authors
- Maha Dardouri (ORCID: https://orcid.org/0000-0002-8766-1527)
- Gina D. Moore (ORCID: https://orcid.org/0000-0002-2096-1058)
- Joseph J. Saseen (ORCID: https://orcid.org/0000-0003-0341-5140)
- Michael J. DiStefano (ORCID: https://orcid.org/0000-0002-5021-5347)
- Kavita V. Nair (ORCID: https://orcid.org/0009-0009-0201-1495)
Institutions
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1080/20523211.2024.2441220
- Citations
- 3
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.34